Fourth Quarter 2025 Financial Results This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's 2026 financial framework, including up to ten percent revenue growth and further cost reductions in 2026; Moderna's year-end cash balance; Moderna's multi-year revenue growth strategy; Moderna's expectations regarding durable growth supported by strategic agreements and global approvals; M ...

Core Viewpoint - Moderna continues to target a 10% revenue growth for the year, indicating a positive outlook despite recent financial performance [1] Financial Performance - The company's fourth-quarter loss has narrowed compared to the same period last year, suggesting improvements in financial health [1]

Core Viewpoint - Moderna reported better-than-expected sales performance of its COVID-19 vaccine in the U.S., leading to fourth-quarter revenue exceeding Wall Street expectations [1][2]. Group 1: Financial Performance - The company's quarterly revenue was $678 million, surpassing the analyst average expectation of $626.1 million [2]. - Moderna has faced financial pressure due to a significant decline in COVID-19 vaccine demand following the pandemic [1]. Group 2: Future Outlook - The company reiterated its expectation for a 10% revenue growth in 2026 [2]. - Moderna is actively developing new products to fill the revenue gap and demonstrate the long-term viability of its mRNA technology [1].

格隆汇2月13日｜Moderna第四季度营收6.78亿美元，同比下降30%，市场预期6.251亿美元。第四季度每 股亏损2.11美元，去年同期每股亏损2.91美元。预计全年营收同比增长最高可达10%。预计全年资本支 出为2亿至3亿美元，市场预期为2.653亿美元。 ...

Core Insights - Moderna reported a fourth-quarter loss of $2.11 per share, indicating financial challenges for the company [1] - The company's revenue for the quarter was $678 million, reflecting a significant decline compared to previous periods [1] Financial Performance - The reported loss of $2.11 per share highlights the company's struggle to maintain profitability [1] - Revenue of $678 million suggests a downturn in sales, which may impact future growth prospects [1]

莫德纳：该公司目标是到2026年实现相较于2025年营收最高达10%的增长。 来源：滚动播报 ...

Core Insights - Moderna reported fourth-quarter revenue of $678 million, exceeding Wall Street estimates of $626.1 million, driven by better-than-expected sales of its COVID-19 vaccine in the U.S. [1] - The company is facing financial challenges as demand for COVID vaccines has declined significantly since the pandemic peak, prompting efforts to develop new products to sustain revenue and demonstrate the long-term viability of its mRNA technology [1] - Moderna reiterated its expectation of achieving 10% revenue growth by 2026 [1]

Revenue Expectations - Moderna expects approximately $1.9 billion in revenue for the fiscal year ended December 31, 2025[4] Operating Expenses - The company anticipates GAAP operating expenses of $5.0 - $5.2 billion for the fiscal year ended December 31, 2025[4] Financial Position - Moderna's expected cash, cash equivalents, and investments in marketable securities as of December 31, 2025, is approximately $8.1 billion[4]

Core Insights - The company reported fourth quarter revenue of $0.7 billion, with a GAAP net loss of $(0.8) billion and a GAAP EPS of $(2.11) [1] - For the full year, revenue was $1.9 billion, with a GAAP net loss of $(2.8) billion and a GAAP diluted EPS of $(7.26) [1] - The company reiterated its plan to achieve up to 10% revenue growth and reduce GAAP operating expenses by 2026 [1] Regulatory and Clinical Updates - The company announced that its influenza vaccine filing has been accepted for regulatory review in the EU, Canada, and Australia; however, it received a Refusal-to-File letter from the U.S. FDA and has requested a Type A meeting to clarify the path forward [1] - The Norovirus Phase 3 trial is fully enrolled, with data readout expected in 2026 [1] - Full enrollment of the Phase 2 intismeran autogene trial in muscle invasive bladder cancer has been achieved [1] Business Developments - In 2025, the company focused on sharpening its commercial execution, launched its third product, and brought online three international manufacturing sites while advancing its mRNA pipeline [1]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Moderna reported better-than-expected fourth quarter sales and affirmed revenue growth estimates for 2026 despite soft demand for its COVID-19 vaccine and recent, high-profile pushback from the Food and Drug Administration. The biotechnology company said Friday it recorded revenue of $678 million over the final three months of last year and $1.9 billion for a ...